

Author Index (Vol. 83)

Abiko, T., see Nishida, K. (83) 119
Arai, M., see Shiomi, M. (83) 69
Araki, S.-i., Kawahara, Y., Fukuzaki, H. and Takai, Y.
Serotonin plays a major role in serum-induced phospholipase C-mediated hydrolysis of phosphoinositides and DNA synthesis in vascular smooth muscle cells (83) 29
Aro, A., Teirilä, J. and Gref, C.-G.
Dose-dependent effect on serum cholesterol and apoprotein B concentrations by consumption of boiled, non-filtered coffee (83) 257
Asai, K., see Naito, M. (83) 9

Bak, A.A.A., Van Vliet, H.H.D.M. and Grobbee, D.E.
Coffee, caffeine and hemostasis: results from two randomized studies (83) 249
Ballantine, J.A., see Carpenter, K.L.H. (83) 217
Becker, P., see Sewdarsen, M. (83) 111
Beilin, L.J., see Croft, K.D. (83) 101
Berger, I., see Singer, P. (83) 167
Blankenhorn, D.H., see Chin, H.P. (83) 1

Carlson, L.A., see Johansson, J. (83) 207
Carpenter, K.L.H., Ballantine, J.A., Fussell, B., Enright, J.H. and Hutchinson, M.J.
Oxidation of cholesterol linoleate by human monocyte-macrophages in vitro (83) 217
Caslake, M.J., see Griffin, B.A. (83) 59
Chin, H.P., Liu, C.R., Liu, C.H. and Blankenhorn, D.H.
Very early aortic responses during atherosclerosis induction in rabbits: measurement by duplex ultrasound. I. Non-invasive study of aortic hyperresponsiveness to serotonin (83) 1
Croft, K.D., Beilin, L.J., Vandongen, R., Rouse, I. and Masarei, J.
Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolemia (83) 101

Dachet, C., see Lontie, J.-F. (83) 187
De Knijff, P., Stalenhoef, A.F.H., Mol, M.J.T.M., Gevers Leuven, J.A., Smit, J., Erkelen, D.W., Schouten, J., Frants, R.R. and Havekes, L.M.
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia (83) 89
Desai, R.K., see Sewdarsen, M. (83) 111
Donner, M., see Muller, S. (83) 231
Dregelid, E., see Svendsen, E. (83) 239

Drouin, P., see Muller, S. (83) 231
Dubois, D.Y., see Lontie, J.-F. (83) 187

Ehringer, H., see Koppensteiner, R. (83) 53
Eide, G.E., see Svendsen, E. (83) 239
Enright, J.H., see Carpenter, K.L.H. (83) 217
Erkelen, D.W., see De Knijff, P. (83) 89

Ferezou, J., see Lontie, J.-F. (83) 187
Frants, R.R., see De Knijff, P. (83) 89
Frants, R.R., see Top, B. (83) 127
Fukami, M., see Shiomi, M. (83) 69
Fukushige, J., see Shiomi, M. (83) 69
Fukuzaki, H., see Araki, S.-i. (83) 29
Funaki, C., see Naito, M. (83) 9
Fussell, B., see Carpenter, K.L.H. (83) 217

Gaffney, D., see Mendis, S. (83) 21
Gevers Leuven, J.A., see De Knijff, P. (83) 89
Gevers Leuven, J.A., see Top, B. (83) 127
Gillies, P.J., Robinson, C.S. and Rathgeb, K.A.
Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: implications for drug discovery (83) 177
Gref, C.-G., see Aro, A. (83) 257
Griffin, B.A., Caslake, M.J., Yip, B., Tait, G.W., Packard, C.J. and Shepherd, J.
Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation (83) 59
Grobbee, D.E., see Bak, A.A.A. (83) 249

Haba, T., see Takegoshi, T. (83) 99
Hamada, M., Kusuyama, Y., Nishio, I., Ura, M., Takeda, J., Hano, T. and Masuyama, Y.
Effect of centrifugal force and catecholamines on glycosaminoglycans synthesis of vascular smooth muscle cells in culture (83) 147
Hano, T., see Hamada, M. (83) 147
Hara, H. and Howard, B.V.
Characterization of LDL binding in TR 715-19 cells. A high capacity, stable line for evaluating the binding of LDL to the human LDL receptor (83) 155
Havekes, L.M., see De Knijff, P. (83) 89
Havekes, L.M., see Top, B. (83) 127
Hayashi, T., see Naito, M. (83) 9

Hiebert, L.M. and Liu, J.-m.
Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites (83) 47

Hirai, J.-i., see Takegoshi, T. (83) 99

Hixson, J.E., see Thieszen, S.L. (83) 137

Howard, B.V., see Hara, H. (83) 155

Hughes, L.O., Wojciechowski, A.P. and Raftery, E.B.
Relationship between plasma cholesterol and coronary artery disease in Asians (83) 15

Ishihara, M., see Nishida, K. (83) 119

Ito, T., see Shiomi, M. (83) 69

James, R.W. and Pometta, D.
Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations (83) 35

Jialal, I., see Sewdarsen, M. (83) 111

Johansson, J. and Carlson, L.A.
The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects (83) 207

Kawahara, Y., see Araki, S.-i. (83) 29

Keller, C., see Rauh, G. (83) 81

Kitoh, C., see Takegoshi, T. (83) 99

Koelman, B.P.C., see Top, B. (83) 127

Koppensteiner, R., Minar, E. and Ehringer, H.
Effect of lovastatin on hemorheology in type II hyperlipoproteinemia (83) 53

Kuroda, M., see Shiomi, M. (83) 69

Kusuyama, Y., see Hamada, M. (83) 147

Kuzuya, F., see Naito, M. (83) 9

Kuzuya, M., see Naito, M. (83) 9

Lee, R.M.K.W.
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation (83) 263

Liu, C.H., see Chin, H.P. (83) 1

Liu, C.R., see Chin, H.P. (83) 1

Liu, J.-m., see Hiebert, L.M. (83) 47

Lontie, J.-F., Malmendier, C.L., Serouge, C., Dubois, D.Y., Dachet, C., Ferezou, J. and Mathé, D.
Plasma lipids, lipoproteins and apolipoproteins in two kindreds of hypobetalipoproteinemia (83) 187

Mabuchi, H., see Takegoshi, T. (83) 99

Malmendier, C.L., see Lontie, J.-F. (83) 187

Masarei, J., see Croft, K.D. (83) 101

Masuyama, Y., see Hamada, M. (83) 147

Mathé, D., see Lontie, J.-F. (83) 187

McCully, K.S., Olszewski, A.J. and Vezeridis, M.P.
Homocysteine and lipid metabolism in atherosclerosis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide (83) 197

McManus, B.M., see Thieszen, S.L. (83) 137

Mendis, S., Shepherd, J., Packard, C.J. and Gaffney, D.
Genetic variation in the cholesterol ester transfer protein and apolipoprotein A-I genes and its relation to coronary heart disease in a Sri Lankan population (83) 21

Minar, E., see Koppensteiner, R. (83) 53

Mitchinson, M.J., see Carpenter, K.L.H. (83) 217

Mol, M.J.T.M., see De Knijff, P. (83) 89

Müller, B., see Rauh, G. (83) 81

Muller, S., Ziegler, O., Donner, M., Drouin, P. and Stoltz, J.F.
Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia (83) 231

Nagengast, D.J., see Thieszen, S.L. (83) 137

Naito, M., Hayashi, T., Kuzuya, M., Funaki, C., Asai, K. and Kuzuya, F.
Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro (83) 9

Nishida, K., Abiko, T., Ishihara, M. and Tomikawa, M.
Arterial injury-induced smooth muscle cell proliferation in rats is accompanied by increase in polyamine synthesis and level (83) 119

Nishio, I., see Hamada, M. (83) 147

Olszewski, A.J., see McCully, K.S. (83) 197

Packard, C.J., see Griffin, B.A. (83) 59

Packard, C.J., see Mendis, S. (83) 21

Pometta, D., see James, R.W. (83) 35

Raftery, E.B., see Hughes, L.O. (83) 15

Rathgeb, K.A., see Gillies, P.J. (83) 177

Rauh, G., Schuster, H., Müller, B., Schewe, S., Keller, C., Wolfram, G. and Zöllner, N.
Genetic evidence from 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia (83) 81

Robinson, C.S., see Gillies, P.J. (83) 177

Rouse, I., see Croft, K.D. (83) 101

Saga, T., see Takegoshi, T. (83) 99

Schewe, S., see Rauh, G. (83) 81

Schouten, J., see De Knijff, P. (83) 89

Schuster, H., see Rauh, G. (83) 81

Serouge, C., see Lontie, J.-F. (83) 187

Sewdarsen, M., Vythilingum, S., Jialal, I., Desai, R.K. and Becker, P.
Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men (83) 111

Shepherd, J., see Griffin, B.A. (83) 59

Shepherd, J., see Mendis, S. (83) 21

Shiomi, M., Ito, T., Watanabe, Y., Tsujita, Y., Kuroda, M., Arai, M., Fukami, M., Fukushima, J. and Tamura, A.
Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine (83) 69

Singer, P., Wirth, M. and Berger, I.
 A possible contribution of decrease in free fatty acids to low serum triglyceride levels after diets supplemented with $n-6$ and $n-3$ polyunsaturated fatty acids (83) 167

Smit, J., see De Knijff, P. (83) 89

Stalenhoef, A.F.H., see De Knijff, P. (83) 89

Stoltz, J.F., see Muller, S. (83) 231

Svendsen, E., Dregelid, E. and Eide, G.E.
 Internal elastic membrane in the internal mammary and left anterior descending coronary arteries and its relationship to intimal thickening (83) 239

Tait, G.W., see Griffin, B.A. (83) 59

Takai, Y., see Araki, S.-i. (83) 29

Takeda, J., see Hamada, M. (83) 147

Takegoshi, T., Haba, T., Hirai, J.-i., Kitoh, C., Saga, T., Yamazaki, Y. and Mabuchi, H.
 Alterations of lipoprotein(a) in patients with diabetic nephropathy (83) 99

Tamura, A., see Shiomi, M. (83) 69

Teirilä, J., see Aro, A. (83) 257

Thieszen, S.L., Hixson, J.E., Nagengast, D.J., Wilson, J.E. and McManus, B.M.
 Lipid phenotypes, apolipoprotein genotypes and cardiovascular risk in nonagenarians (83) 137

Tomikawa, M., see Nishida, K. (83) 119

Top, B., Koeleman, B.P.C., Gevers Leuven, J.A., Havekes, L.M. and Frants, R.R.
 Rearrangements in the LDL receptor gene in Dutch familial hypercholesterolemic patients and the presence of a common 4 kb deletion (83) 127

Tsujita, Y., see Shiomi, M. (83) 69

Ura, M., see Hamada, M. (83) 147

Vandongen, R., see Croft, K.D. (83) 101

Van Vliet, H.H.D.M., see Bak, A.A.A. (83) 249

Vezeridis, M.P., see McCully, K.S. (83) 197

Vythilingum, S., see Sewdarsen, M. (83) 111

Watanabe, Y., see Shiomi, M. (83) 69

Wilson, J.E., see Thieszen, S.L. (83) 137

Wirth, M., see Singer, P. (83) 167

Wojciechowski, A.P., see Hughes, L.O. (83) 15

Wolfram, G., see Rauh, G. (83) 81

Yamazaki, Y., see Takegoshi, T. (83) 99

Yip, B., see Griffin, B.A. (83) 59

Ziegler, O., see Muller, S. (83) 231

Zöllner, N., see Rauh, G. (83) 81

Subject Index (Vol. 83)

Acyl-CoA:cholesterol acyltransferase, (83) 177
 Aorta, (83) 1
 Apolipoprotein A-I, (83) 35
 Apolipoprotein A-II, (83) 35
 Apolipoprotein B, (83) 81
 Apolipoprotein E, (83) 89
 Apolipoproteins, (83) 137; (83) 187
 Arachidonic acid, (83) 167
 Arterial injury, (83) 119
 Artificial lipoprotein, (83) 217
 Asians, (83) 15
 Atherogenesis, (83) 101; (83) 197
 Atherosclerosis, (83) 9; (83) 29; (83) 35; (83) 69; (83) 147; (83) 217
 Blood pressure, (83) 167
 Blood viscosity, (83) 231
 Body mass index, (83) 137
 Caffeine, (83) 249
 Cardiovascular system, (83) 249
 Catecholamines, (83) 147
 Cell migration, (83) 9
 Cells cultured, (83) 147
 Chemotaxis, (83) 9
 Cholest-5-en-3 β ,7 β -diol, (83) 217
 Cholesterol, (83) 15; (83) 89
 Cholesterol substrate pool, (83) 177
 Cholestrylin, (83) 217
 Cholestyramine, (83) 69
 Coffee, (83) 249; (83) 257
 Combination drug treatment, (83) 69
 Coronary artery, (83) 239
 Coronary artery disease, (83) 15; (83) 59
 Coronary atherosclerosis, (83) 21
 Density gradient ultracentrifugation, (83) 59; (83) 187
 Diet, (83) 137
 Direct sequencing, (83) 127
 Eicosanoid, (83) 101
 Eicosapentaenoic acid, (83) 167
 Endothelial injury, (83) 47
 Erythrocyte aggregation, (83) 231
 Erythrocyte membrane, (83) 231
 Experimental atherosclerosis, (83) 1
 Familial combined hyperlipidemia, (83) 81
 Familial hypercholesterolemia, (83) 89
 Fibrin, (83) 9
 Fibrinogen, (83) 9; (83) 53
 Fluorescence polarization, (83) 231
 Founder effect, (83) 127
 FPLC gel filtration, (83) 187
 Free fatty acids, (83) 167
 Genetic polymorphism, (83) 89
 Glycosaminoglycans, (83) 147
 Gradient gel electrophoresis, (83) 59; (83) 207
 Growth factor, (83) 29
 Haptotaxis, (83) 9
 HDL, (83) 21
 HDL subclasses, (83) 35
 Hemostasis, (83) 249
 Heparin, (83) 47
 High density lipoproteins, (83) 35; (83) 207
 Homocysteine, (83) 197
 Hypercholesterolemia, (83) 101
 Hyperlipidaemia, (83) 207
 Hyperlipoproteinemia, (83) 231
 Hyperlipoproteinemia, type II, (83) 53
 Hypertension, (83) 147
 Hypobetalipoproteinemia, (83) 187
 Hypolipidemic effect, (83) 69
 Immunoaffinity chromatography, (83) 187
 Immunoblotting, (83) 187
 Immunofractionation, (83) 35
 Internal elastic membrane, (83) 239
 Internal mammary artery, (83) 239
 Intimal thickening, (83) 239
 Leukocyte, (83) 101
 Linoleic acid, (83) 167
 Lipid fluidity, (83) 231
 Lipid oxidation, (83) 217
 Lipids, (83) 137
 Lipoproteins, (83) 137; (83) 187
 Longevity, (83) 137
 Low density lipoprotein subfractions, (83) 59
 Macrophages, (83) 217
 Marine oil, (83) 1
 Monocytes, (83) 217
 Morphometry, (83) 239
 Myocardial infarction, (83) 111

Nicotinic acid, (83) 207
Nonagenarian, (83) 137
Ornithine decarboxylase, (83) 119

Oxygen metabolites, (83) 47

Pathogenesis, (83) 9
Plasma viscosity, (83) 53; (83) 231
Platelet, (83) 101; (83) 231
Platelet activating factor, (83) 101
Polyamines, (83) 119
Polymerase chain reaction, (83) 127
Pravastatin sodium, (83) 69
Progression, (83) 177

Randomized study, (83) 249
Red cell aggregation, (83) 53
Regression, (83) 177

Restriction fragment length polymorphism, (83) 21; (83) 137
RFLP, (83) 81
Risk factors, (83) 111; (83) 137
RNA splicing, (83) 127

Serotonin, (83) 1; (83) 29
Serum apoproteins, (83) 257
Serum cholesterol, (83) 257

Serum lipids, (83) 197
Serum lipoproteins, (83) 257
Serum triglycerides, (83) 167
Sex hormones, (83) 111
Simvastatin, (83) 89
Smooth muscle cell proliferation, (83) 119
Smooth muscle cells, (83) 9
Southern analysis, (83) 127
Spontaneously hypertensive rats, (83) 147

Thioretinaco, (83) 197
Thioretinamide, (83) 197
Treatment, (83) 207
Triceps skinfold, (83) 137
Two-dimensional immunoelectrophoresis, (83) 187

Ultrasound, (83) 1

Vascular smooth muscle cell proliferation, (83) 29
Vascular smooth muscle cells, (83) 147
Vessel wall stress, (83) 239

WHHL rabbit, (83) 69

Xanthoma, (83) 69